Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Chimeric antigen receptor dendritic cells targeted delivery of a single tumoricidal factor for cancer immunotherapy

Cancer Immunology Immunotherapy(2024)10.1007/s00262-024-03788-1Source: DataRank Database

Chimeric antigen receptor dendritic cells targeted delivery of a single tumoricidal factor for cancer immunotherapy is a research paper published in Cancer Immunology Immunotherapy (2024). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 2.49)OA: goldTopics (56)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Philip Milton ORCID,Chutamath Sittplangkoon ORCID,Xin Liu ORCID,Zhining Sui,Brendan F. Boyce ORCID

Live enrichment

PubMed:39105847 PMC:PMC11303651 OpenAlex:https://openalex.org/W4401413516

National Institutes of Health grant

Grant: R01AG076731

National Institutes of Health grant

Grant: R01AG049994

U.S. Department of Defense Breast Cancer Research Program

Grant: W81XWH-22-1-0049

New York State Department of Health Breast Cancer Research Project

Grant: C34928GG

NIAMS NIH HHS

Grant: P30 AR069655

FWCI

2.49

Citation Percentile

0.9%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://link.springer.com/content/pdf/10.1007/s00262-024-03788-1.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00262-024-03788-1.pdf

publisherhttps://link.springer.com/article/10.1007/s00262-024-03788-1/fulltext.html

journalhttps://doi.org/10.1007/s00262-024-03788-1

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39105847

Fields of Study

CAR-T cell therapy researchImmunotherapy and Immune ResponsesCell death mechanisms and regulationHumansAnimalsMiceDendritic CellsFemaleReceptors, Chimeric AntigenTumor Necrosis Factor-alphaMucin-1Xenograft Model Antitumor AssaysCell Line, TumorInhibitor of Apoptosis ProteinsImmunotherapy, AdoptiveApoptosisBreast NeoplasmsImmunotherapyNeoplasmsMice, SCID

MeSH Terms

Receptors, Chimeric AntigenAnimalsBreast NeoplasmsDendritic CellsFemaleHumansImmunotherapyNeoplasmsTumor Necrosis Factor-alphaImmunotherapy, AdoptiveMice, SCIDApoptosisMucin-1Xenograft Model Antitumor AssaysCell Line, TumorInhibitor of Apoptosis ProteinsMice

Keywords

ImmunotherapyChimeric antigen receptorCancer immunotherapyImmunologyCancerAntigenCancer researchDendritic cellMedicineImmune systemInternal medicineBreast cancerMucin1Dendritic Cell (Dc)Iap AntagonistInhibitor Of Apoptosis Proteins (Iaps)Tumor Necrosis Factor-α (Tnf)Chimeric Antigen Receptor (Car) Cell TherapyPatient-derived Xenograft (Pdx) Model

Sustainable Development Goals

SDG 0: Good health and well-being